e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xeris Biopharma Holdings, Inc. - Common Stock
(NQ:
XERS
)
8.200
-0.110 (-1.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xeris Biopharma Holdings, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
August 25, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris (XERS) Q2 Revenue Jumps 49%
August 07, 2025
Via
The Motley Fool
Traders are paying attention to the gapping stocks in Thursday's session.
August 07, 2025
Let's have a look at the gap up and gap down stocks in today's session.
Via
Chartmill
Earnings Scheduled For August 7, 2025
August 07, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
May 08, 2025
Via
Benzinga
Earnings Outlook For Xeris Biopharma Holdings
May 07, 2025
Via
Benzinga
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance
August 07, 2025
Xeris Biopharma (XERS) Q2 2025 results beat estimates with $71.5M revenue (+48.8% YoY) and narrower losses. Stock surged 12.2% pre-market as Recorlev sales soared 136%. Raised full-year guidance to...
Via
Chartmill
Topics
Earnings
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
August 07, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
July 31, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A Strong Growth Candidate Meeting Minervini’s Criteria
July 07, 2025
XERIS Biopharma (XERS) meets Minervini’s Trend Template with strong technicals and high growth momentum, including 47.9% quarterly revenue growth and a 93.95 Relative Strength score.
Via
Chartmill
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
June 03, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Details for Analyst & Investor Day
May 20, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A High-Growth Stock Meeting Minervini’s Trend Template
May 13, 2025
XERIS BIOPHARMA (XERS) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors.
Via
Chartmill
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
May 08, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
May 01, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
April 17, 2025
From
Bright Peak Therapeutics, Inc.
Via
GlobeNewswire
Would Mark Minervini consider XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) a top stock pick?
April 07, 2025
Why the high growth investor may take a look at XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS). A fundamental and technical analysis of (NASDAQ:XERS).
Via
Chartmill
Xeris Announces Changes to Its Board of Directors
March 28, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
March 17, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma - Possibly The Best Pharma Stock
March 11, 2025
The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies.
Via
Talk Markets
Topics
Stocks / Equities
Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In
March 06, 2025
The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.
Via
Stocktwits
These stocks are gapping in today's session
March 06, 2025
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via
Chartmill
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance
March 06, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025
February 27, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
February 24, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Earnings Scheduled For March 6, 2025
March 06, 2025
Via
Benzinga
Xeris to Participate in Upcoming Investor Conferences
February 05, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
January 10, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 06, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
Facebook
Twitter
YouTube